Opthea Ltd (OPT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Opthea Ltd (OPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013559
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Opthea Ltd (Opthea), formerly Circadian Technologies Ltd is a provider of research and development of angiogenesis and vascular leakage-based treatments for cancer focusing on vascular endothelial growth factors. The company’s pipeline products comprise VEGF-C, VEGF-D and VEGFR-3. Opthea’s diagnostic service portfolio includes diagnosis of cancers of unknown primaries. Its lead compound, OPT-302 is used to blocks two members of the vascular endothelial growth factors, namely VEGF-C and VEGF-D which cause blood vessels to grow and leak. The company’s VEGF-D diagnostics is a prognostic indicator of number of tumor types, and VEGF-C diagnostics, an indicator of survival rate. It partners with healthcare and diagnostic centers. Circadian is headquartered in Melbourne, Victoria, Australia.

Opthea Ltd (OPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Opthea Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Opthea Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Opthea Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Opthea Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Opthea Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Opthea Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Opthea Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Opthea Enters Into Licensing Agreement With Selexis For Wet AMD Product 11
Equity Offering 12
Opthea Raises USD2.3 Million in Rights Offering of Shares 12
Opthea Raises USD26.7 Million in Private Placement of Shares 13
Opthea Raises USD5.3 Million in Rights Offering of Shares 14
Circadian Raises USD11.1 Million in Second Tranche of Private Placement of Shares 15
Circadian Raises USD3 Million in Rights Offering of Shares 17
Circadian Technologies Raises USD1 Million in First Tranche of Private Placement 19
Circadian Technologies Completes Private Placement Of Shares For US$1 Million 20
Opthea Ltd – Key Competitors 21
Opthea Ltd – Key Employees 22
Opthea Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Opthea Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Opthea Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Opthea Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Opthea Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Opthea Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Opthea Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Opthea Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Opthea Enters Into Licensing Agreement With Selexis For Wet AMD Product 11
Opthea Raises USD2.3 Million in Rights Offering of Shares 12
Opthea Raises USD26.7 Million in Private Placement of Shares 13
Opthea Raises USD5.3 Million in Rights Offering of Shares 14
Circadian Raises USD11.1 Million in Second Tranche of Private Placement of Shares 15
Circadian Raises USD3 Million in Rights Offering of Shares 17
Circadian Technologies Raises USD1 Million in First Tranche of Private Placement 19
Circadian Technologies Completes Private Placement Of Shares For US$1 Million 20
Opthea Ltd, Key Competitors 21
Opthea Ltd, Key Employees 22
Opthea Ltd, Subsidiaries 23

★海外企業調査レポート[Opthea Ltd (OPT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dunelm Group plc (DNLM):企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Celina Insurance Group:企業の戦略・SWOT・財務分析
    Celina Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Celina Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Agios Pharmaceuticals Inc (AGIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • China Oilfield Services Ltd (2883):企業の財務・戦略的SWOT分析
    China Oilfield Services Ltd (2883) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Totally Plc (TLY):企業の財務・戦略的SWOT分析
    Summary Totally Plc (Totally) is a healthcare service provider that offers positive health and financial solutions. The center designs, implements and delivers coaching services to the healthcare sector, and supports individuals to better understand their healthcare options. It offers treatments and …
  • Lysogene SAS (LYS):製薬・医療:M&Aディール及び事業提携情報
    Summary Lysogene SAS (Lysogene) is a clinical research center that offers basic research and clinical development programs. The center offers clinical development of gene therapy for neurodegenerative disorders such as Parkinson and Alzheimer diseases. It also develops models in gene therapy trials …
  • PharmaZell GmbH:企業の戦略的SWOT分析
    PharmaZell GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Delegat’s Group Limited:戦略・SWOT・企業財務分析
    Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report Summary Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Weyerhaeuser Company:企業の戦略・SWOT・財務情報
    Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report Summary Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Hanmi Pharmaceuticals Co Ltd (128940)-医療機器分野:企業M&A・提携分析
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • Adynxx Inc (ADYX):企業の財務・戦略的SWOT分析
    Summary Adynxx Inc (Adynxx), formerly known as Alliqua BioMedical, Inc, is a clinical stage biopharmaceutical company. It utilizes AYX transcription factor decoys to create therapies with disease changing properties. The company is involved in the development of transcription factor decoy technology …
  • Tokyu Land Corporation:企業の戦略・SWOT・財務情報
    Tokyu Land Corporation - Strategy, SWOT and Corporate Finance Report Summary Tokyu Land Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Heron Therapeutics Inc (HRTX)-医療機器分野:企業M&A・提携分析
    Summary Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused therapeutic products for patients suffering from cancer and pain. Its proprietary Biochronomer technology is …
  • Rite Aid Corp (RAD)-製薬・医療分野:企業M&A・提携分析
    Summary Rite Aid Corp (Rite Aid) is retail drugstore chain. The company sells prescription drugs and a wide range of other merchandise such as, over-the-counter (OTC) medications, personal care items, health and beauty aids, cosmetics, household items, beverages, convenience foods, greeting cards, s …
  • Fremont Michigan InsuraCorp Inc.:企業の戦略・SWOT・財務情報
    Fremont Michigan InsuraCorp Inc. - Strategy, SWOT and Corporate Finance Report Summary Fremont Michigan InsuraCorp Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Desitin Arzneimittel GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Desitin Arzneimittel GmbH (Desitin) formerly Desitin Compagnie mbH, is a specialty pharmaceutical company which develops and produces products for the treatment of central nervous system (CNS) related neurological and psychiatric diseases. Its product portfolio includes antiepileptic drugs a …
  • Gritstone Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Gritstone Oncology Inc (Gritstone) is a cancer immunotherapy company that focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neo-antigens from individual patients’ tumors for the development of novel …
  • B.O.S. Better OnLine Solutions Ltd (BOSC):企業の財務・戦略的SWOT分析
    Summary B.O.S. Better OnLine Solutions Ltd (B.O.S) is a technology company that offers RFID and supply chain solutions. The company provides RFID and mobile solutions such as automatic identification data capture (AIDC) and radio frequency identification (RFID) hardware, mobile solutions, software a …
  • Sorgenia SpA:企業の戦略的SWOT分析
    Sorgenia SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Harley-Davidson Inc (HOG):企業の財務・戦略的SWOT分析
    Harley-Davidson Inc (HOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆